See more : L’Oréal S.A. (LRLCF) Income Statement Analysis – Financial Results
Complete financial analysis of NanoVibronix, Inc. (NAOV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoVibronix, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- LottoGopher Holdings Inc. (LTTGF) Income Statement Analysis – Financial Results
- Clean Earth Acquisitions Corp. (CLINU) Income Statement Analysis – Financial Results
- USDATA Corp. (USDC) Income Statement Analysis – Financial Results
- Newcore Gold Ltd. (NCAUF) Income Statement Analysis – Financial Results
- VIS Co., Ltd. (5071.T) Income Statement Analysis – Financial Results
NanoVibronix, Inc. (NAOV)
About NanoVibronix, Inc.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was incorporated in 2003 and is based in Elmsford, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.28M | 752.00K | 1.70M | 623.00K | 530.00K | 318.00K | 239.00K | 229.00K | 147.00K | 203.00K | 211.00K | 166.00K | 94.00K |
| Cost of Revenue | 746.00K | 585.00K | 925.00K | 409.00K | 249.00K | 158.00K | 88.00K | 88.00K | 49.00K | 93.00K | 91.00K | 50.00K | 29.00K |
| Gross Profit | 1.54M | 167.00K | 770.00K | 214.00K | 281.00K | 160.00K | 151.00K | 141.00K | 98.00K | 110.00K | 120.00K | 116.00K | 65.00K |
| Gross Profit Ratio | 67.32% | 22.21% | 45.43% | 34.35% | 53.02% | 50.31% | 63.18% | 61.57% | 66.67% | 54.19% | 56.87% | 69.88% | 69.15% |
| Research & Development | 185.00K | 283.00K | 293.00K | 171.00K | 514.00K | 614.00K | 693.00K | 584.00K | 399.00K | 431.00K | 620.00K | 572.00K | 510.00K |
| General & Administrative | 3.92M | 3.93M | 5.06M | 3.77M | 3.82M | 2.64M | 2.08M | 1.36M | 747.00K | 589.00K | 366.00K | 128.00K | 87.00K |
| Selling & Marketing | 864.00K | 965.00K | 1.10M | 993.00K | 1.10M | 1.21M | 465.00K | 514.00K | 377.00K | 301.00K | 244.00K | 190.00K | 150.00K |
| SG&A | 4.79M | 4.90M | 6.16M | 4.76M | 4.92M | 3.85M | 2.55M | 1.87M | 1.12M | 890.00K | 610.00K | 318.00K | 237.00K |
| Other Expenses | 0.00 | 0.00 | -1.63M | 42.00K | -412.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.00K | 0.00 | 0.00 |
| Operating Expenses | 4.97M | 5.18M | 6.45M | 4.93M | 5.43M | 4.46M | 3.24M | 2.46M | 1.52M | 1.32M | 1.23M | 890.00K | 747.00K |
| Cost & Expenses | 5.72M | 5.76M | 7.38M | 5.34M | 5.68M | 4.62M | 3.33M | 2.55M | 1.57M | 1.41M | 1.32M | 940.00K | 776.00K |
| Interest Income | 0.00 | 54.00K | 48.00K | 147.00K | 15.00K | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 1.00K | 1.00K |
| Interest Expense | 246.00K | 347.00K | 0.00 | 147.00K | 62.00K | 22.00K | 1.23M | 0.00 | 65.00K | 372.00K | 782.00K | 256.00K | 21.00K |
| Depreciation & Amortization | 1.00K | 1.00K | 2.00K | 2.00K | 4.00K | 6.00K | 5.00K | 7.00K | 9.00K | 9.00K | 10.00K | 9.00K | 10.00K |
| EBITDA | -3.44M | -5.01M | -14.25M | -4.16M | -5.75M | -4.28M | -3.64M | -2.69M | -2.38M | -1.33M | -1.23M | -1.01M | -692.00K |
| EBITDA Ratio | -150.46% | -673.54% | -433.98% | -757.14% | -1,048.87% | -1,344.34% | -1,313.39% | -1,014.85% | -1,238.10% | -1,024.14% | -771.56% | -608.43% | -736.17% |
| Operating Income | -3.44M | -5.01M | -5.68M | -4.72M | -5.15M | -4.30M | -3.09M | -2.32M | -1.42M | -1.21M | -1.11M | -774.00K | -682.00K |
| Operating Income Ratio | -150.50% | -666.49% | -335.28% | -757.46% | -971.89% | -1,353.14% | -1,293.31% | -1,011.35% | -968.71% | -596.55% | -526.07% | -466.27% | -725.53% |
| Total Other Income/Expenses | -246.00K | -401.00K | -8.57M | 408.00K | -660.00K | 22.00K | -1.84M | -398.00K | -1.43M | -1.39M | -844.00K | -501.00K | -41.00K |
| Income Before Tax | -3.68M | -5.41M | -14.25M | -4.31M | -5.81M | -4.28M | -4.93M | -2.71M | -2.86M | -2.60M | -1.95M | -1.28M | -723.00K |
| Income Before Tax Ratio | -161.28% | -719.81% | -840.71% | -691.97% | -1,096.42% | -1,346.23% | -2,061.51% | -1,185.15% | -1,942.86% | -1,279.80% | -926.07% | -768.07% | -769.15% |
| Income Tax Expense | 29.00K | 35.00K | 32.00K | 15.00K | -17.00K | -127.00K | 38.00K | 117.00K | 28.00K | 49.00K | 35.00K | 10.00K | -20.00K |
| Net Income | -3.71M | -5.45M | -14.28M | -4.33M | -5.79M | -4.15M | -4.97M | -2.83M | -2.88M | -2.65M | -1.99M | -1.28M | -723.00K |
| Net Income Ratio | -162.55% | -724.47% | -842.60% | -694.38% | -1,093.21% | -1,306.29% | -2,077.41% | -1,236.24% | -1,961.90% | -1,303.94% | -942.65% | -768.07% | -769.15% |
| EPS | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| EPS Diluted | -2.12 | -3.84 | -11.35 | -8.40 | -16.70 | -12.88 | -20.00 | -12.37 | -16.31 | -20.27 | -15.23 | -9.77 | -5.54 |
| Weighted Avg Shares Out | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
| Weighted Avg Shares Out (Dil) | 1.75M | 1.42M | 1.26M | 514.91K | 346.97K | 322.42K | 248.20K | 228.92K | 176.82K | 130.57K | 130.57K | 130.57K | 130.57K |
NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (“SAW”) Portable Ultrasonic Therapeutic Devices, today announced it has signed a non-binding term sheet for a license and...
NanoVibronix Signs Letter of Intent with Potential New Distributor
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV) (the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has signed a letter of intent with Medici Medical LTD...
NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that the University of Michigan will begin the pilot phase of its clinical...
NanoVibronix Issues Letter to Stockholders
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to its stockholders from its Chief Executive Officer, Brian Murphy, providing...
NanoVibronix Announces Distribution Agreement with VA Supplier CB Medical for the Distribution of UroShield
TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix,” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a distribution agreement with...
NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024
1x1 Meetings on Thursday, May 2, 2024 ELMSFORD, NY / ACCESSWIRE / April 24, 2024 / NanoVibronix, Inc. (Nasdaq:NAOV) ("NanoVibronix" or the "Company"), a medical device company that produces the UroShieldâ, PainShieldâ and WoundShieldâ Surface Acoustic Wave (SAW) Portable Ultrasonic...
NanoVibronix Issues Letter to Stockholders
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV)(“NanoVibronix”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today issued a letter to stockholders from its Chief Executive Officer, Brian Murphy, providing a...
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (Nasdaq: NAOV) (“NanoVibronix” or the “Company”), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it has entered into an agreement with Veranex, Inc....
NanoVibronix Featured in Your Bladder Health Magazine
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield is featured in Issue 103 of Your Bladder Health Magazine...
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
ELMSFORD, N.Y.--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has entered into a non-binding letter of intent (the “LOI”) with...
Source: https://incomestatements.info
Category: Stock Reports